A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes
Eli Lilly and Company
600 participants
May 19, 2025
INTERVENTIONAL
Conditions
Summary
The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part of the master protocol study J2A-MC-GZPO. Participation in the study will last about 18 months.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Administered orally
Administered orally
Locations(77)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06972472